Dry eyes, which is a very common phenomenon these days characterized by inadequate tears in the eye, can be treated by number of methods such as medical device therapies, medications, and surgical interventions. The dry eye disease is something which many individuals experience sometime or the other in his or her lifetime. Dry eye is a problem which needs to be treated because insufficient lubrication of the eye causes redness, burning sensation, as well as pain in the eye. It is caused by Meibomian Gland Dysfunction (MGD) wherein there is an insufficiency of the tear producing glands. According to a recent research report by a research firm called Transparency Market Research (TMR), the global dry eyes disease market will exhibit a 4.5% CAGR in the period from 2017 to 2025 reaching an evaluation of US$7.78 bn by the end of 2025,

Factors responsible for the growth of the dry eyes disease market

From many years now, dry eyes has become increasingly prevalent among people across all age groups. This is obviously helping the market to grow. In addition to this, the growing awareness among the people regarding the medications available, the introduction of technologically advanced diagnostic tools, and the involvement of the treatment administered for treating dry eyes are some of the other factors aiding the growth of the global dry eye disease market. Leading players within the market are launching effective eye drops such as Restasis and Ikervis. Other players have started directing their efforts for the development of novel therapeutics for treating the inflammation of the eye. Growing investments in R&D and for the development of devices such as drug-eluting contact lenses and drug loaded punctual plugs will propel the growth of the dry eyes disease market.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26096

Among the different products such as artificial tears anti-inflammatory drugs, it is the latter which will contribute the maximum to the revenue of the global dry eye disease market. The introduction of various new and inflammatory drugs such as Lifitegrast (Xiidra) will be a key reason for the growth of this segment. The advancements in the existing eye drops such as cyclosporine will also lead to the expansion of anti-inflammatory drugs segment.

Rrecent developments in the dry eye disease market

Recently, in vitro models are being used for obtaining a thorough understanding of dry eyes disease related inflammatory processes at the cellular level. Advanced Techniques such as conjunctivitis biopsy, multiplex tear analysis, and impression cytology are some of the ways which have resulted in improved assessment of the inflammation among patients suffering from dry eye disease. The latest strategy is to focus on breaking the inflammatory cycle perpetuating the ocular surface disease which has led to the development of anti-inflammatory compounds that show promising results. Agents such as corticosteroids and essential fatty acids which have anti-inflammatory properties are also being used and proven to show positive results.